IAVI

KAVI Institute of Clinical Research enrolled the first volunteer to start a phase 1 clinical trial to test a novel HIV vaccine candidate, BG505 SOSIP.664 gp140.

The study dubbed the International AIDS Vaccine Initiative W001 (IAVI W001) is aimed at assessing the safety of the candidate and to determine if vaccination induces the human immune system to produce proteins known as neutralizing antibodies (NAbs).